Cross-talks among GBA mutations,glucocerebrosidase,and a-synuclein in 66/4-associated Parkinson's disease and their targeted therapeutic approaches:a comprehensive review  

作　　者：Tapan Behl Gagandeep Kaur Ovidiu Fratila Camelia Buhas Claudia Teodora Judea-Pusta Nicoleta Negrut Cristiana Bustea Simona Bungau 

机构地区：[1]Chitkara College of Pharmacy,Chitkara University,Rajpura,Punjab,India [2]Departm ent of Medical Disciplines,Faculty of Medicine and Pharmacy,University of Oradea,Oradea,Romania [3]Department of Morphological Disciplines,Faculty of Medicine and Pharmacy,University of Oradea,Oradea,Bihor County,Romania [4]Departm ent of Psycho-Neuroscience and Recovery,Faculty of Medicine and Pharmacy,University of Oradea,Oradea,Romania [5]Department of Preclinical Disciplines,Faculty of Medicine and Pharmacy,University of Oradea,Oradea,Romania [6]Department of Pharmacy,Faculty of Medicine and Pharmacy,University of Oradea,Oradea,Romania

出　　处：《Translational Neurodegeneration》2021年第1期27-39,共13页转化神经变性病（英文）

摘　　要：Current therapies for Parkinson's disease(PD)are palliative,of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration.Due to the complication of such a multifactorial disorder and significant limitations of the therapy,numerous genetic approaches have been proved effective in finding out genes and mechanisms implicated in this disease.Following the observation of a higher frequency of PD in Gaucher's disease(GD),a lysosomal storage condition,mutations of glycosylceramidase beta(GBA)encoding glucocerebrosidase(GCase)have been shown to be involved and have been explored in the context of PD.GBA mutations are the most common genetic risk factor of PD.Various studies have revealed the relationships between PD and GM gene mutations,facilitating a better understanding of this disorder.Various hypotheses delineate that the pathological mutations of GBA minimize the enzymatic activity of GCase,which affects the proliferation and clearance of α-synuclein;this affects the lysosomal homeostasis,exacerbating the endoplasmic reticulum stress or encouraging the mitochondrial dysfunction.Identification of the pathological mechanisms underlying the GM-associated parkinsonism(GBA+PD)advances our understanding of PD.This review based on current literature aims to elucidate various genetic and clinical characteristics correlated with GBA mutations and to identify the numerous pathological processes underlying GBA+PD.We also delineate the therapeutic strategies to interfere with the mutant GCase function for further improvement of the related asynuclein-GCase crosstalks.Moreover,the various therapeutic approaches such as gene therapy,chaperone proteins,and histone deacetylase inhibitors for the treatment of GBA+PD are discussed.

关 键 词：Parkinson's disease Glycosylceramidase GLUCOCEREBROSIDASE Gaucher's disease MUTATIONS Α-SYNUCLEIN 

分 类 号：R742.5[医药卫生—神经病学与精神病学]